PMADS

Id:	acc4840
Group:	1sens
Protein:	alpha-synuclein
Gene Symbol:	SNCA
Protein Id:	P37840
Protein Name:	SYUA_HUMAN
PTM:	phosphorylation
Site:	Ser129
Site Sequence:	PDNEAYEMPSEEGYQDYEPEA
Disease Category:	Nervous system diseases
Disease:	Parkinson's Disease
Disease Subtype:	LRRK2 G2019S?mutation mDAN
Disease Cellline:
Disease Info:
Drug:	PFE-360
Drug Info:	PFE - 360 is a drug. It may have specific medical functions and applications.
Effect:	modulate
Effect Info:	"Treatment with PFE - 360 and MLi - 2 can reduce the phosphorylation and aggregation of aSyn by inhibiting LRRK2 kinase activity, potentially alleviating the progression of PD."
Note:
Score:	4.0
Pubmed(PMID):	36179692
Sentence Index:	36179692_3
Sentence:	"Using automated fluorescence microscopy in 384-well-plate format, we identified elevated levels of alpha-synuclein (alphaSyn) and serine 129 phosphorylation, reduced dendritic complexity, and mitochondrial dysfunction."

Sequence & Structure:

MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
SNCA	CINPANEMAB	Alpha-synuclein inhibitor	2	Terminated	Parkinson disease	ClinicalTrials
SNCA	PRASINEZUMAB	Alpha-synuclein binding agent	2	Active, not recruiting	Parkinson disease	ClinicalTrials ClinicalTrials
SNCA	CINPANEMAB	Alpha-synuclein inhibitor	1	Completed	Parkinson disease	ClinicalTrials
SNCA	CINPANEMAB	Alpha-synuclein inhibitor	1	Terminated	Parkinson disease	ClinicalTrials
SNCA	PRASINEZUMAB	Alpha-synuclein binding agent	1	Completed	Parkinson disease	ClinicalTrials ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

SNCA-Tyr39
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC

SNCAIP-Ser269
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

SNCAIP-Ser286
Cancer	Intensity
BRCA	1.033
COAD
HGSC
ccRCC
GBM
HNSC	-0.069
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.964

SNCAIP-Ser607
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

SNCAIP-Ser609
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

SNCAIP-Ser610
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

SNCAIP-Ser612
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

SNCAIP-Ser613
Cancer	Intensity
BRCA	-0.257
COAD
HGSC
ccRCC
GBM	1.103
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.846

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb